Home/Filings/4/0001246360-19-000765
4//SEC Filing

Swan Winifred L 4

Accession 0001246360-19-000765

CIK 0001333170other

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 5:49 PM ET

Size

17.9 KB

Accession

0001246360-19-000765

Insider Transaction Report

Form 4
Period: 2019-02-21
Swan Winifred L
SVP and General Counsel
Transactions
  • Disposition to Issuer

    Common Stock

    2019-02-21$30.00/sh13,077$392,3100 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-02-2111,5420 total
    Exercise: $11.03From: 2013-04-04Exp: 2023-03-03Common Stock (11,542 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-02-2149,5290 total
    Exercise: $14.66From: 2014-04-10Exp: 2024-03-09Common Stock (49,529 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    2019-02-219,3140 total
    Exercise: $0.00From: 2018-03-09Exp: 2020-03-09Common Stock (13,971 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-02-2153,3150 total
    Exercise: $16.66From: 2015-04-03Exp: 2025-03-02Common Stock (53,315 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-02-2171,5090 total
    Exercise: $15.58From: 2016-04-09Exp: 2026-03-08Common Stock (71,509 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-02-2139,8840 total
    Exercise: $27.89From: 2017-04-09Exp: 2027-03-08Common Stock (39,884 underlying)
Footnotes (3)
  • [F1]Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
  • [F2]This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
  • [F3]These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share.

Issuer

NxStage Medical, Inc.

CIK 0001333170

Entity typeother

Related Parties

1
  • filerCIK 0001341405

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 5:49 PM ET
Size
17.9 KB